CoChat

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion. In the CHIEF-HF trial ( NCT04252287 ), 476 participants with HF, regardless of EF or diabetes status, were randomized to 100 mg of canagliflozin or placebo. Enrollment was stopped early due to shifting sponsor priorities, without unblinding. The primary outcome was change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at 12 weeks. The 12-week change in KCCQ TSS was 4.3 points (95% confidence interval, 0.8–7.8; P = 0.016) higher with canagliflozin than with placebo, meeting the primary endpoint. Similar effects were observed in participants with HFpEF and in those with HFrEF and in participants with and without diabetes, demonstrating that canagliflozin significantly improves symptom burden in HF, regardless of EF or diabetes status. This randomized, double-blind trial, conducted without in-person interactions between doctor and patient, can serve as a model for future all-virtual clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01703-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study CONSORT diagram showing the process of subject participation. KCCQ, Kansas City Cardiomyopathy Questionnaire.
Fig. 1 Study CONSORT diagram showing the process of subject participation. KCCQ, Kansas City Cardiomyopathy Questionnaire.CC BY · PubMed Central
Fig. 2 KCCQ TSS over time. Mean changes in KCCQ TSSs (error bars represent standard errors) at 2, 4, 6 and 12 weeks after randomization.
Fig. 2 KCCQ TSS over time. Mean changes in KCCQ TSSs (error bars represent standard errors) at 2, 4, 6 and 12 weeks after randomization.CC BY · PubMed Central
Fig. 3 Effects of treatment by HF type and diabetes status. Estimates of the mean difference in KCCQ TSSs by subgroups are stratified by EF and diabetes status. In total, 208 participants were treated with canagliflozin and 206 with placebo. T2DM, type 2 diabetes mellitus.
Fig. 3 Effects of treatment by HF type and diabetes status. Estimates of the mean difference in KCCQ TSSs by subgroups are stratified by EF and diabetes status. In total, 208 participants were treated with canagliflozin and 206 with placebo. T2DM, type 2 diabetes mellitus.CC BY · PubMed Central
Extended Data Fig. 1 Distributions of 3-month Changes in KCCQ Total Symptom Scores. The proportions of patients experiencing the indicated magnitudes of clinical change are shown. KCCQ=Kansas City Cardiomyopathy Questionnaire.
Extended Data Fig. 1 Distributions of 3-month Changes in KCCQ Total Symptom Scores. The proportions of patients experiencing the indicated magnitudes of clinical change are shown. KCCQ=Kansas City Cardiomyopathy Questionnaire.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 286

Metadata

Authors
Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L.
Affiliations
  • University of Missouri–Kansas City (US)
  • Janssen Scientific Affairs (United States) (US)
  • Janssen Research & Development (United States) (US)
  • Virginia Commonwealth University (US)
  • University of Mississippi Medical Center (US)
  • Henry Ford Health (US)
  • The University of Texas Southwestern Medical Center (US)
  • Harvard University (US)
Corresponding author
Spertus, John A.
Venue
Nature Medicine
Published
2022-02-28
Volume
28
Issue
4
Pages
809-813
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4214512384
Cited by
245
References
32
Citations by year
2026: 27 · 2025: 43 · 2024: 64 · 2023: 68 · 2022: 42
FWCI
37.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
canagliflozin, SGLT2 inhibitors, heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, Kansas City Cardiomyopathy Questionnaire, symptom burden, remote clinical trials, COVID-19 pandemic, diabetes mellitus, early trial termination
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, COVID-19, Heart Failure, Humans, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Patient-Centered Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. https://app.cochat.ai/papers/10.1038/s41591-022-01703-8
The paper
Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01703-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.